VIP
vasoactive intestinal peptide · aviptadil · C147H238N44O42S · monoisotopic 3324.8146 Da. The index holds 4 assay reports on this compound across 2 batches from 2 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
VIP is the least stable compound the index tracks in solution: measurable degradation within hours at room temperature in unbuffered water. Reports must state the interval between reconstitution and injection, and the index excludes VIP records where that interval exceeded four hours from the purity aggregates while still publishing the record. Thin coverage, n under 40.
- Compound class
- Tissue-repair and immunomodulatory peptides
- Molecular formula
- C147H238N44O42S
- Monoisotopic mass
- 3324.8146Da
- Average mass
- 3326.83Da
- Residues
- 28
- Nominal retention (RG-2, 30 min)
- 12.98min
- Retention window
- 0.35min
- Counter-ion as usually shipped
- acetate
- Typical label claims
- 1 mg · 2 mg · 5 mg
- Analytical difficulty (index scale)
- 1.15 — moderate
- Purity is a defined quantity
- YES
Representative chromatogram
Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.
What the index has observed
Arithmetic over the 4 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
Fewer than twelve purity records (n=4) — a histogram of this would be a picture of the sample size rather than of the compound. The individual values are in the table below.
By supplier
Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| Met17 sulfoxide (+16 Da) | -0.66 | +15.995 | 100% | 0.63 | 1.77 |
| C-terminal free acid (+1 Da) | +0.28 | +0.984 | 100% | 0.38 | 0.52 |
| des-His1 (−137 Da) | -0.82 | -137.059 | 100% | 0.16 | 0.34 |
| deamidated (+1 Da) | -0.30 | +0.984 | 100% | 0.32 | 0.84 |
Degradation pathways
- Met17 oxidation
- C-terminal amide hydrolysis
- rapid aqueous instability — hours, not days
Full impurity profile, with what each named species implies about the synthesis →
Clinical context
Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.
Aviptadil was studied for COVID-19-associated respiratory failure; results did not support approval.
Quarterly coverage
Most recent records
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2025-019161 | TFC | TFC-2503-E5248 | Janoshik | 2025-Q2 | 98.65 | 3.88 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2025-019160 | TFC | TFC-2503-E5248 | Nordanalyt | 2025-Q2 | 99.34 | 3.52 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2024-005474 | BCH | BCH-2405-R6960 | Janoshik | 2024-Q3 | 97.80 | 5.85 | 103.4 | Supplier-supplied | 1 | MARGINAL |
| AX-2024-005475 | BCH | BCH-2405-R6960 | Medutest | 2024-Q3 | 97.32 | 5.45 | — | Supplier-supplied | 2 | FAIL |